Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) EBIT Margin (2023 - 2025)

Historic EBIT Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Q3 2025 value amounting to 140.69%.

  • Iovance Biotherapeutics' EBIT Margin rose 114200.0% to 140.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 166.31%, marking a year-over-year increase of 3069100.0%. This contributed to the annual value of 240.92% for FY2024, which is 384940700.0% up from last year.
  • Iovance Biotherapeutics' EBIT Margin amounted to 140.69% in Q3 2025, which was up 114200.0% from 189.78% recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' EBIT Margin ranged from a high of 117.48% in Q4 2024 and a low of 46254.62% during Q2 2023
  • In the last 3 years, Iovance Biotherapeutics' EBIT Margin had a median value of 286.7% in 2024 and averaged 11428.64%.
  • Per our database at Business Quant, Iovance Biotherapeutics' EBIT Margin soared by 459269900bps in 2024 and then surged by 114200bps in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' EBIT Margin (Quarter) stood at 25156.85% in 2023, then soared by 100bps to 117.48% in 2024, then fell by -20bps to 140.69% in 2025.
  • Its last three reported values are 140.69% in Q3 2025, 189.78% for Q2 2025, and 245.76% during Q1 2025.